PD1及PDL1在乳腺癌中的表达变化及其与患者临床病理参数和预后的关系

Expression of PD1 and PDL1 in breast cancer and its relationship with clinicopathological parameters and prognosis

目的探讨程序性死亡受体1(PD1)及细胞程序性死亡配体1(PDL1)在乳腺癌中的表达情况及其与患者临床病理参数、预后的关系。方法回顾性选取2017年2月至2019年2月新疆维吾尔自治区人民医院收治的乳腺癌患者186例。检测乳腺癌组织和癌旁组织PD1及PDL1表达情况,分析乳腺癌组织PD1及PDL1表达情况及其与临床病理参数、预后的关系。结果乳腺癌组织PD1及PDL1表达阳性率为79.57%、79.57%,均高于癌旁组织(48.39%、22.58%),阴性率为20.43%、20.43%,均低于癌旁组织(51.61%、77.42%),差异均有统计学意义(P<0.05)。组织学分级Ⅱ级、Ⅲ级患者的乳腺癌组织PD1表达阳性率为87.10%、87.18%,高于Ⅰ级患者(56.52%),有淋巴结转移患者的乳腺癌组织PD1表达阳性率为90.48%,高于无淋巴结转移患者(70.59%),差异均有统计学意义(P<0.05)。临床分期Ⅲ~Ⅴ期患者的乳腺癌组织PDL1表达阳性率为93.55%,高于Ⅰ~Ⅱ期患者(72.58%),组织学分级Ⅱ级、Ⅲ级患者的乳腺癌组织PDL1表达阳性率为87.18%、83.87%,高于Ⅰ级患者(60.87%),差异均有统计学意义(P<0.05)。乳腺癌组织PD1及PDL1表达阳性患者的生存时间为(29.80±1.07)、(30.48±1.03)个月,均短于阴性患者[(34.73±1.22)、(34.04±1.36)个月],3年生存率59.46%、60.81%,均低于阴性患者(94.74%、84.21%),差异均有统计学意义(P<0.05)。结论PD1及PDL1在乳腺癌中的表达阳性率增高,且与患者临床病理参数、预后的关系密切。

Objective To investigate the expression of Programmed death receptor 1(PD1)and programmed cell death ligand 1(PDL1)in breast cancer and its relationship with clinicopathological parameters and prognosis.Methods A retrospective study of 186 breast cancer patients in People's Hospital of Xinjiang Uygur Autonomous Region from February 2017 to February 2019 was performed to statistically analyze the expression of PD1 and PDL1 in breast cancer tissues and adjacent tissues,and the expression of PD1 and PDL1 in breast cancer tissues were detected,and its relationship with clinicopathological parameters and prognosis were analyzed.Results The positive rates of PD1 and PDL1 expression in breast cancer tissues were 79.57%and 79.57%,which were higher than those in adjacent tissues(48.39%and 22.58%),and the negative rates were 20.43%and 20.43%,which were lower than those in adjacent tissues(51.61%and 77.42%),the differences were statistically significant(P<0.05).The positive rate of PD1 expression in breast cancer tissue of patients with histological gradeⅡandⅢwas 87.10%and 87.18%,which was higher than that of grade I(56.52%),the positive rate of PD1 expression in breast cancer tissue of patients with lymph node metastasis was 90.48%,which was higher than that of patients without lymph node metastasis(70.59%),and the differences were statistically significant(P<0.05).The positive rate of PDL1 expression in breast cancer tissue of patients with clinical stageⅢ-V was 93.55%,which was higher than that of patients with stage I-Ⅱ(72.58%),the positive rates of PDL1 expression in breast cancer tissue of patients with histological gradeⅡandⅢwere 87.18%,83.87%,which were higher than those of grade I(60.87%),and the differences were statistically significant(P<0.05).The survival time of patients with positive PD1 and PDL1 expression in breast cancer tissues was(29.80±1.07),(30.48±1.03)months,which were shorter than those of negative patients[(34.73±1.22),(34.04±1.36)months],and the 3-year survival rates were 59.46%and 60.81%,which were lower than those of negative patients(94.74%and 84.21%),and the differences were statistically significant(P<0.05).Conclusion The positive expression rate of PD1 and PDL1 in breast cancer is high,which is closely related to clinicopathological parameters and prognosis of patients.